{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:14:47Z","timestamp":1770228887147,"version":"3.49.0"},"reference-count":55,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the pattern of anti\u2010calcitonin gene\u2013related peptide monoclonal antibodies (anti\u2010CGRP mAbs) utilization in the Tuscany region, Italy, and the variation of triptan consumption after treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Given the recent commercialization of anti\u2010CGRP mAbs as migraine preventive medications, real\u2010world evidence on their patterns of utilization and their impact on migraine abortive medication use is still limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, descriptive, cohort study on the real\u2010world utilization of anti\u2010CGRP mAbs was performed using the population\u2010based regional administrative database of Tuscany. Patients with \u22651 anti\u2010CGRP mAb dispensing (namely erenumab, galcanezumab, fremanezumab) between April 1, 2019, and September 30, 2021, were identified. The first dispensing was the cohort entry (CE). New users (NUs) were patients with no anti\u2010CGRP mAb dispensing before CE. Kaplan\u2013Meier (KM) curves were plotted to describe the cumulative probability of remaining with the initial anti\u2010CGRP mAb during a 15\u2010month follow\u2010up period as a measure of treatment persistence. Among NUs with \u22652 triptan dispensings during the 6\u2009months before CE (i.e., baseline), the mean monthly number of triptan dosage units dispensed was measured in five consecutive follow\u2010up time windows (months 1\u20133, 4\u20136, 7\u20139, 10\u201312, 13\u201315) and the difference from the baseline was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 624 NUs (erenumab\u2009=\u2009295, galcanezumab\u2009=\u2009223, fremanezumab\u2009=\u2009106) were identified, of whom 188 (78%) were women. Mean age was 49.2\u2009years (standard deviation [SD]\u2009=\u200912.6). The survival to discontinuation at 6, 12, and 15\u2009months was about 69%, 48%, and 6%, respectively. The survival to switch was about 6% at 15\u2009months. The observed variation of triptan consumption at 3\/6\/9\/12\/15\u2009months and the corresponding SD was \u22124.4 [8.2]\/\u22125.2 [9.0]\/\u22125.5 [9.2]\/\u22125.4 [9.2]\/\u22124.5 [10.0], respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patient demographics reflect the place of these medications in therapy. Overall, findings seem to indicate a favorable tolerability and effectiveness profile. Further studies are warranted to better establish the long\u2010term comparative effectiveness, safety, and cost effectiveness of anti\u2010CGRP mAbs compared to other preventive medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14639","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:50:55Z","timestamp":1697190655000},"page":"1391-1402","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patterns of anti\u2010CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-2083","authenticated-orcid":false,"given":"Giulia","family":"Hyeraci","sequence":"first","affiliation":[{"name":"Agenzia regionale di sanit\u00e0 della Toscana (ARS)  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Paoletti","sequence":"additional","affiliation":[{"name":"Agenzia regionale di sanit\u00e0 della Toscana (ARS)  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[{"name":"Section of Clinical Pharmacology and Oncology, Department of Health Sciences University of Florence  Florence Italy"},{"name":"Headache Centre, Department of Health Sciences, Careggi University Hospital University of Florence  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[{"name":"Agenzia regionale di sanit\u00e0 della Toscana (ARS)  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"De\u00a0Cesaris","sequence":"additional","affiliation":[{"name":"Headache Centre, Department of Health Sciences, Careggi University Hospital University of Florence  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierangelo","family":"Geppetti","sequence":"additional","affiliation":[{"name":"Section of Clinical Pharmacology and Oncology, Department of Health Sciences University of Florence  Florence Italy"},{"name":"Headache Centre, Department of Health Sciences, Careggi University Hospital University of Florence  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Roberto","sequence":"additional","affiliation":[{"name":"Agenzia regionale di sanit\u00e0 della Toscana (ARS)  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Gazzetta Ufficiale_Aimovig. Accessed January 18 2021.https:\/\/www.gazzettaufficiale.it\/eli\/id\/2020\/07\/21\/20A03784\/sg"},{"key":"e_1_2_11_3_1","unstructured":"Gazzetta Ufficiale_Emgality. Accessed January 18 2021.https:\/\/www.gazzettaufficiale.it\/eli\/id\/2020\/07\/21\/20A03782\/sg"},{"key":"e_1_2_11_4_1","unstructured":"Gazzetta Ufficiale_Ajovy. Accessed January 18 2021.https:\/\/www.gazzettaufficiale.it\/eli\/id\/2020\/07\/21\/20A03783\/sg"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2013"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","unstructured":"Calcitonin Gene\u2010Related Peptide (CGRP) Mechanisms: Focus on Migraine. SpringerLink. Accessed March 6 2023. doi:10.1007\/978-3-030-21454-8","DOI":"10.1007\/978-3-030-21454-8"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419844711"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28204-z"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12618"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420966658"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_2_11_14_1","unstructured":"aimovig\u2010epar\u2010product\u2010information_en.pdf. Accessed January 26 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/aimovig\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_15_1","unstructured":"emgality\u2010epar\u2010product\u2010information_en.pdf. Accessed January 26 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/emgality\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_16_1","unstructured":"ajovy\u2010epar\u2010product\u2010information_en.pdf. Accessed January 26 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ajovy\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_17_1","unstructured":"Emgality_scheda registro."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231160519"},{"issue":"35","key":"e_1_2_11_20_1","article-title":"Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)","volume":"22","author":"Vernieri F","year":"2021","journal-title":"J Headache Pain"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01102-9"},{"issue":"69","key":"e_1_2_11_22_1","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real\u2010world experience","volume":"21","author":"Russo A","year":"2020","journal-title":"J Headache Pain"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05426-5"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14032"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14194"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15563"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01561-w"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2476"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-019-0334-y"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0732-5"},{"key":"e_1_2_11_31_1","unstructured":"Anagrafe Utenti \u2010 Regione Toscana. Accessed February 6 2023.https:\/\/www.regione.toscana.it\/\u2010\/16\u2010anagrafe\u2010utenti"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14463"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.11.015"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00409-9"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01413-z"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158163211020419"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00893-y"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211008401"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01238-2"},{"issue":"50","key":"e_1_2_11_42_1","article-title":"Medication\u2010overuse headache: a widely recognized entity amidst ongoing debate","volume":"19","author":"Vandenbussche N","year":"2018","journal-title":"J Headache Pain"},{"key":"e_1_2_11_43_1","unstructured":"Legge 648\/1996. Accessed May 17 2023.https:\/\/aifa.gov.it\/legge\u2010648\u201096"},{"key":"e_1_2_11_44_1","unstructured":"Aimovig_scheda registro."},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211046617"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01363-y"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S346660"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14218"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06199-1"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158163211040061"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2012.04.128"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S104807"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S163037"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-012-0437-6"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00319-z"},{"key":"e_1_2_11_56_1","volume-title":"A Validation Odyssey: from Big Data to Local Intelligence Validity of Case Finding Algorithms and of Measures of Quality of Care for Chronic Diseases in Italian Administrative Databases","author":"Gini R","year":"2016"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:59:00Z","timestamp":1762084740000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/head.14639"],"URL":"https:\/\/doi.org\/10.1111\/head.14639","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"2023-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}